Giant cell tumor of bone: A clinicopathologic study of prognostic factors

Masui, Fumiaki; Ushigome, Shinichiro; Fujii, Katsuyuki

doi:10.1111/j.1440-1827.1998.tb03973.x

Cited by 75 publications

(74 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies analyzing subpopulations of recurrent GCTs found lung metastases in as much as 10% [3,45]. With seven of 46 patients, the frequency of pulmonary metastases was higher in our study than previously reported for primary and recurrent tumors [3,4,8,10,18,28,36,41,45]. The development of pulmonary metastases was independent of the type of surgery chosen for recurrent disease.…”

Section: Discussioncontrasting

confidence: 52%

“…The overall frequency of lung metastases in patients with GCTs ranges from 2% to 5%, and the risk of having lung metastases develop seems to be associated with local recurrence [4,8,10,18,28,36,41]. Studies analyzing subpopulations of recurrent GCTs found lung metastases in as much as 10% [3,45].…”

Section: Discussionmentioning

confidence: 99%

“…Despite their generally benign nature, GCTs are able to seed lung metastases. The frequency of lung metastases ranges from 2% to 5% and the risk for development of lung metastases seems to be associated with local recurrence [4,5,8,10,18,28,34,36,38,41]. In rare occasions, patients can have lung metastases with fatal progression.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Recurrent Giant Cell Tumor of Long Bones: Analysis of Surgical Management

Klenke

Wenger

Inwards

et al. 2011

Clinical Orthopaedics &Amp; Related Research

115

106

View full text Add to dashboard Cite

Background Treatment of giant cell tumor of bone (GCT) often is complicated by local recurrence. Intralesional curettage is the standard of care for primary GCTs. However, there is controversy whether intralesional curettage should be preferred over wide resection in recurrent GCTs. Questions/purposes We investigated the rerecurrencefree survival after surgical treatment of recurrent GCTs to determine the influence of the surgical approach, adjuvant treatment, local tumor presentation, and demographic factors on the risk of further recurrence. Patients and Methods We retrospectively reviewed the medical records of 46 patients with recurrent GCTs of long bones treated with wide resection or intralesional curettage and compared these cohorts. Recurrence rates, risk factors for recurrence, and the development of pulmonary metastases were determined. The minimum followup was 37 months (mean, 134 months; range, 37-337 months).

show abstract

Section: Discussioncontrasting

confidence: 52%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Recurrent Giant Cell Tumor of Long Bones: Analysis of Surgical Management

Klenke

Wenger

Inwards

et al. 2011

Clinical Orthopaedics &Amp; Related Research

115

106

View full text Add to dashboard Cite

show abstract

“…However, it has not been possible to provide any definite prognostic significance in terms of clinical course [28,55], and the grading system is not generally accepted. DNA cytometry has led to contradictory results, and most publications decline to accept its prognostic significance [26,34,44].…”

Section: Histology and Biological Behaviourmentioning

confidence: 99%

Giant cell tumour of bone: morphological, biological and histogenetical aspects

Werner

2006

International Orthopaedics (SICOT)

212

156

View full text Add to dashboard Cite

The giant cell tumour of bone (GCT) is a locally aggressive intraosseous neoplasm of obscure biological behaviour. Although well defined in clinical, radiological and histological terms, detailed information on its biological development is still relatively incomplete. The tumoral tissue consists of three cell types -the neoplastic giant cell tumour stromal cells (GCTSC), representing the proliferative fraction, secondarily recruited mononuclear histiocytic cells (MNHC) and multinuclear giant cells (MNGC). These cellular components interact together with factors that have a role in regulating osteoclast function in normal bone tissue (e.g. RANK, RANKL, OPG, M-CSF). Recent publications suggest that the neoplastic stromal cells express differentiation features of mesenchymal stem cells. Further research of the pathogenesis of GCT as well as the complex interactions of its cellular populations may provide the knowledge necessary for developing approaches for a biological-based therapy of this neoplasm.Résumé Les tumeurs à cellules géantes (GCT) sont des tumeurs localement agressives de type néoplasme intra osseux don't les mécanismes biologiques restent relativement obscurs. Cependant si ces tumeurs sont bien définies sur le plan clinique, radiologique et histologique, les détails marquants de leur développement biologique restent inconnus. Le tissu tumoral consiste en un stroma de tumeurs à cellules géantes (GCTSC) qui représente la partie prolifér-ative de la tumeur avec adjonction secondaire de cellules de type histogitaire mononuclées (MNHC) et de cellules géantes (MNGC). Ces composants cellulaires interagissent avec un certain nombre de facteurs régulant l'action ostéoclastique du tissu osseux normal (e.g. RANK, RANKL, OPG, M-CSF). De récentes publications permettent de penser que ce stroma cellulaire de type néoplasique exprime une différenciation de cellules mésenchymateuses. De prochaines recherches sur la pathogénèse des tumeurs à cellules géantes ainsi que sur les interactions complexes des différentes populations cellulaires devraient permettre d'approcher un traitement médical pour ce type de néoplasme.

show abstract

“…Local recurrence rates after resection and bulk allograft reconstruction have been reported to be as low as 0 percent [5,9]. Reported local recurrence rates after intralesional procedures have ranged from 0 to 52 percent [1,2,4,5,8,9,13,15,[18][19][20][21]25]. Factors associated with obtaining local control have included the use of a burr [2], phenol [5,16,22], electrocautery [25], cryosurgery [22], hydrogen peroxide [25], autograft bone [2,[19][20][21], allograft bone [2,[19][20][21], and polymethylmethacrylate bone cement (PMMA) [1,4,16,20].…”

Section: Introductionmentioning

confidence: 99%